Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy

Jeffrey R. Curtis, Barbara Smith, Michael Weaver, Kathleen Landers, Robert Lopez-Ben, James L. Raper, Michael Saag, Rajesh Venkataraman, Kenneth G. Saag

Research output: Contribution to journalArticle

14 Scopus citations


A high prevalence of metabolic bone disease and osteonecrosis among HIV+ patients on highly active antiretroviral therapy (HAART) has been reported in predominantly white cohorts. We examined bone health in an ethnically diverse cohort of 23 African-Americans and 21 non-African-Americans who were mean (standard deviation) age 45 (7) years old, 66% male, and on HAART for 34 (28) months. Non-African-Americans were more likely to have osteopenia or osteoporosis (59%) compared to African-Americans (26%) (p = 0.09). The prevalence of vitamin D insufficiency (<34 ng/ml) and elevated i-PTH (>65 pg/ml) was 79% and 20%, respectively. Higher mean urinary N-telopeptide levels were found in non-African-Americans [58 (34) nmol BCE/mmol] compared to African-Americans [41 (18) nmol BCE/mmol] (p = 0.09). Magnetic resonance imaging identified one African-American subject (3%) with bilateral asymptomatic hip osteonecrosis. Our findings suggest that the burden of metabolic bone disease in HIV+ patients with HAART-associated lipodystro-phy may be greater in whites than in African-Americans. Studies to examine ethnic variations in bone metabolism are necessary to devise optimal interventions.

Original languageEnglish (US)
Pages (from-to)125-131
Number of pages7
JournalAIDS Research and Human Retroviruses
Issue number2
StatePublished - Feb 1 2006


ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Curtis, J. R., Smith, B., Weaver, M., Landers, K., Lopez-Ben, R., Raper, J. L., Saag, M., Venkataraman, R., & Saag, K. G. (2006). Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy. AIDS Research and Human Retroviruses, 22(2), 125-131.